- This topic has 1 voice and 0 replies.
Viewing 0 reply threads
-
Posts
-
-
Two years after its approval and with new data from ECTRIMS, Ocrevus is living up to its designation as a “game-changer,” Genentech’s Hideki Garren says. Read more here.
Do you agree that Ocrevus is a “game-changer” for people with MS?
-
Viewing 0 reply threads
- You must be logged in to reply to this topic.
